Key facts
- It has raised $315.0M across 3 recorded rounds; the latest was Later Stage VC (Series D) ($125.0M) in Sep 2025.
- Notable investors include Viking Global Investors, RA Capital Management, OrbiMed, Qatar Investment Authority, Catalio Capital Management — 19 tracked in total.
- Star Therapeutics has filed 1 Form D with the SEC, most recently Oct 2025 ($125.0M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Star Therapeutics
Funding rounds
3 roundsAbout Star Therapeutics
Developer of antibody-based therapeutics designed to treat serious and underserved diseases through novel biological pathways. The company offers a pipeline-in-a-product approach with proprietary antibody platforms, enabling patients with bleeding disorders to benefit from targeted, effective, and patient-centered treatments.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 44
- Website
- star-therapeutics.com/
- Ownership
- Privately Held (backing)
Star Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Star Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Star Therapeutics in its N-PORT filings yet. We sweep new filings monthly.